Influence Explorer

Lobbying on Behalf of Coalition for 21st Century Medicine

• Names of Lobbyists

  • Paul Kim,
  • Nick Littlefield,
  • Sheila Dearybury Walcoff,
  • Paul William Radensky,
  • Eric P. Zimmerman,
  • Andrea Bergman,
  • Brian Carey,

• Most Frequently Disclosed Lobbying Issues

  • Medical Research & Clin Labs,
  • Medicare & Medicaid,
  • Health Issues

• Most Frequently Disclosed Bills

  Bill No.	Title
  H.R.3207	Modernizing Laboratory Test Standards for Patients Act of 2011
  H.R.3207	To amend the Internal Revenue Code of 1986 to exclude from gross income gain on the sale of certain residential leased-fee interests to holders of the leasehold rights.
  S.1220	Patient Access to Critical Lab Tests Act

The tables show occurrences of "Coalition for 21st Century Medicine" in public comments on proposed federal regulations.

• Documents Submitted by the Organization

  • Submissions
  • Agency
  • Docket
  • Date
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]; Availability 2011
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications; Availability 2011
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Review 2011
  • Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
  • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on In Vitro Companion Diagnostic Devices; Availability 2011
View all submissions data for Coalition for 21st Century Medicine Sources: Regulations.gov

• Mentions in Document Text

  • Mentions
  • Agency
  • Docket
  • Date
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]; Availability 2011
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Review 2011
  • Toggle 1 FDA Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability 2011
  • Toggle 1 FDA Draft Guidance for Industry and Food and Drug Administration Staff; Mobile Medical Applications; Availability 2011
  • Toggle 1 CMS Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, DME Face-to-Face Encounters, Elimination of the Requirement for Termination of Non-Random Prepayment Complex Medical Review and Other Revisions to Part B for CY 2013 (CMS-1590-P) 2012
  • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on In Vitro Companion Diagnostic Devices; Availability 2011
View all mentions data for Coalition for 21st Century Medicine Sources: Regulations.gov